Hepatitis B

Diagnosis and treatment

Jeff T Wilkins, Dave Zimmerman, Robert R. Schade

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Although an estimated 1 million persons in the United States are chronically infected with hepatitis B virus, the prevalence of hepatitis B has declined since the implementation of a national vaccination program. Hepatitis B virus is transmitted in blood and secretions. Acute infection may cause nonspecific symptoms, such as fatigue, poor appetite, nausea, vomiting, abdominal pain, low-grade fever, jaundice, and dark urine; and clinical signs, such as hepatomegaly and splenomegaly. Fewer than 5 percent of adults acutely infected with hepatitis B virus progress to chronic infection. The diagnosis of hepatitis B virus infection requires the evaluation of the patient's blood for hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. The goals of treatment for chronic hepatitis B virus infection are to reduce inflammation of the liver and to prevent complications by suppressing viral replication. Treatment options include pegylated interferon alfa-2a administered subcutaneously or oral antiviral agents (nucleotide reverse transcriptase inhibitors). Persons with chronic hepatitis B virus infection should be monitored for disease activity with liver enzyme tests and hepatitis B virus DNA levels; considered for liver biopsy; and entered into a surveillance program for hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)965-972
Number of pages8
JournalAmerican family physician
Volume81
Issue number8
StatePublished - Apr 15 2010

Fingerprint

Hepatitis B
Hepatitis B virus
Virus Diseases
Hepatitis B Antibodies
Chronic Hepatitis B
Therapeutics
Liver
Reverse Transcriptase Inhibitors
Hepatomegaly
Splenomegaly
Appetite
Hepatitis B Surface Antigens
Jaundice
Infection
Nausea
Abdominal Pain
Vomiting
Antiviral Agents
Fatigue
Hepatocellular Carcinoma

ASJC Scopus subject areas

  • Family Practice

Cite this

Wilkins, J. T., Zimmerman, D., & Schade, R. R. (2010). Hepatitis B: Diagnosis and treatment. American family physician, 81(8), 965-972.

Hepatitis B : Diagnosis and treatment. / Wilkins, Jeff T; Zimmerman, Dave; Schade, Robert R.

In: American family physician, Vol. 81, No. 8, 15.04.2010, p. 965-972.

Research output: Contribution to journalArticle

Wilkins, JT, Zimmerman, D & Schade, RR 2010, 'Hepatitis B: Diagnosis and treatment', American family physician, vol. 81, no. 8, pp. 965-972.
Wilkins JT, Zimmerman D, Schade RR. Hepatitis B: Diagnosis and treatment. American family physician. 2010 Apr 15;81(8):965-972.
Wilkins, Jeff T ; Zimmerman, Dave ; Schade, Robert R. / Hepatitis B : Diagnosis and treatment. In: American family physician. 2010 ; Vol. 81, No. 8. pp. 965-972.
@article{37e2a7c69fd349b5909c1c145f335dfe,
title = "Hepatitis B: Diagnosis and treatment",
abstract = "Although an estimated 1 million persons in the United States are chronically infected with hepatitis B virus, the prevalence of hepatitis B has declined since the implementation of a national vaccination program. Hepatitis B virus is transmitted in blood and secretions. Acute infection may cause nonspecific symptoms, such as fatigue, poor appetite, nausea, vomiting, abdominal pain, low-grade fever, jaundice, and dark urine; and clinical signs, such as hepatomegaly and splenomegaly. Fewer than 5 percent of adults acutely infected with hepatitis B virus progress to chronic infection. The diagnosis of hepatitis B virus infection requires the evaluation of the patient's blood for hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. The goals of treatment for chronic hepatitis B virus infection are to reduce inflammation of the liver and to prevent complications by suppressing viral replication. Treatment options include pegylated interferon alfa-2a administered subcutaneously or oral antiviral agents (nucleotide reverse transcriptase inhibitors). Persons with chronic hepatitis B virus infection should be monitored for disease activity with liver enzyme tests and hepatitis B virus DNA levels; considered for liver biopsy; and entered into a surveillance program for hepatocellular carcinoma.",
author = "Wilkins, {Jeff T} and Dave Zimmerman and Schade, {Robert R.}",
year = "2010",
month = "4",
day = "15",
language = "English (US)",
volume = "81",
pages = "965--972",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "8",

}

TY - JOUR

T1 - Hepatitis B

T2 - Diagnosis and treatment

AU - Wilkins, Jeff T

AU - Zimmerman, Dave

AU - Schade, Robert R.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Although an estimated 1 million persons in the United States are chronically infected with hepatitis B virus, the prevalence of hepatitis B has declined since the implementation of a national vaccination program. Hepatitis B virus is transmitted in blood and secretions. Acute infection may cause nonspecific symptoms, such as fatigue, poor appetite, nausea, vomiting, abdominal pain, low-grade fever, jaundice, and dark urine; and clinical signs, such as hepatomegaly and splenomegaly. Fewer than 5 percent of adults acutely infected with hepatitis B virus progress to chronic infection. The diagnosis of hepatitis B virus infection requires the evaluation of the patient's blood for hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. The goals of treatment for chronic hepatitis B virus infection are to reduce inflammation of the liver and to prevent complications by suppressing viral replication. Treatment options include pegylated interferon alfa-2a administered subcutaneously or oral antiviral agents (nucleotide reverse transcriptase inhibitors). Persons with chronic hepatitis B virus infection should be monitored for disease activity with liver enzyme tests and hepatitis B virus DNA levels; considered for liver biopsy; and entered into a surveillance program for hepatocellular carcinoma.

AB - Although an estimated 1 million persons in the United States are chronically infected with hepatitis B virus, the prevalence of hepatitis B has declined since the implementation of a national vaccination program. Hepatitis B virus is transmitted in blood and secretions. Acute infection may cause nonspecific symptoms, such as fatigue, poor appetite, nausea, vomiting, abdominal pain, low-grade fever, jaundice, and dark urine; and clinical signs, such as hepatomegaly and splenomegaly. Fewer than 5 percent of adults acutely infected with hepatitis B virus progress to chronic infection. The diagnosis of hepatitis B virus infection requires the evaluation of the patient's blood for hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. The goals of treatment for chronic hepatitis B virus infection are to reduce inflammation of the liver and to prevent complications by suppressing viral replication. Treatment options include pegylated interferon alfa-2a administered subcutaneously or oral antiviral agents (nucleotide reverse transcriptase inhibitors). Persons with chronic hepatitis B virus infection should be monitored for disease activity with liver enzyme tests and hepatitis B virus DNA levels; considered for liver biopsy; and entered into a surveillance program for hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=79953663171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953663171&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 965

EP - 972

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 8

ER -